LIXT
$3.01
Pre-MarketAs of Mar 17, 8:00 PM UTC
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies.
Historical Price
Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$3.01
Potential Upside
5%
Whystock Fair Value$3.16
Price
UndervaluedFair ValueOvervalued
Fundamentals
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinica...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$26.20M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-130.06%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
5.54
